deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT04656041

Folfox+Irinotecan+Chemort In Esophageal Cancer

A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation With Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer

Sponsor: Ipsen

Conditions Esophagogastric Cancer Gastroesophageal Junction Adenocarcinoma
Interventions Carboplatin FOLFOX/ nal-IRI Paclitaxel Proton Radiation Therapy
Updated 5 times since 2021 Last updated: Nov 12, 2025 Started: Jun 29, 2021 Primary completion: Apr 30, 2024 Completion: Dec 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04656041, this PHASE2 trial focuses on Esophagogastric Cancer and Gastroesophageal Junction Adenocarcinoma and remains actively recruiting participants. Sponsored by Ipsen, it has been updated 5 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshotNot Yet Recruiting~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2025 · 15 months · monthly snapshotRecruiting~Dec 2025 – present · 7 months · monthly snapshotRecruiting

Change History

5 versions recorded

  1. Dec 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2024 — Dec 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Jan 2021 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ipsen
  • Massachusetts General Hospital
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations